Partners
A∙WOL is proud to have research partnerships with leading, like-minded institutions across the globe.
Partners
Our relationship with each partner is unique yet collectively focussed on a common commitment to eradicate disease in NTD endemic regions of the world.
-
AbbVie
AbbVie goes beyond medicine to make an impact in the community through volunteering, corporate culture and the AbbVie Foundation.
-
AstraZeneca
AstraZeneca is committed to developing and implementing scientific advancement in infection and vaccines.
-
Eisai Inc
Eisai believes that it is the mission of modern research and development based pharmaceutical companies to create innovative new medicines and contribute to global health and medicine.
-
The University of Buea
The Faculty of Science is concerned with the pursuit of scientific truth through research and teaching.
-
Universitäts Klinikum Bonn
The group at Bonn study the therapy of filarial infection via the antibiotic elimination of Wolbachia bacteria in parasitic worms.
-
University of California, San Francisco
UCSF conducts macrofilaricide studies to find lead compounds that treat filarial diseases in life cycle stages where current treatment is ineffective.
-
University of Liverpool
The Chemistry Department is internationally known for its research in fields such as materials chemistry, medicinal chemistry, surface chemistry and nanosciences.
-
University of Texas Medical Branch
UTMB are interested in translating their findings in basic research into diagnostic assays that can be used for early identification of debilitating diseases.